The Anti-Defamation League says it's found "millions of examples of extremist and hateful content" on the platform.
EMA committee recommends approval of Eisai & Biogen’s lecanemab to treat early Alzheimer’s disease: Tokyo Saturday, November 16, 2024, 13:00 Hrs [IST] Eisai Co., Ltd. and Biog ...
BioArctic AB (publ) today announces that EMA's Committee for Medicinal Products for Human Use (CHMP) has issued a positive recommendation regarding BioArctic's partner Eisai's marketing authorization ...
1. About lecanemab (generic name, brand name: Leqembi®) Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal ...
Anavex Life Sciences' (AVXL) stock surged on new Alzheimer's trial data, but data's inconsistency raises concerns, making the ...
Anavex announced new data from their phase 2b/3 Alzheimer's trial, which was presented at the CTAD 2024 conference. Read why ...
Participants were broken into two cohorts. The first cohort received one of three doses of PCRX-201. The second cohort received concurrent pretreatment with an intraarticular corticosteroid ...
Family members can get paid to be caregivers for their elderly parents through Medicaid, VA benefits, long-term care ...
US's financial and military support of Israel for decades is the reason why the Zionist state is able to carry out the genocide in Palestine and war crimes in Lebanon.
BioArctic AB's (publ) partner Eisai has presented the latest findings for lecanemab (Leqembi®) at the Clinical Trials on Alzheimer's Disease, CTAD, congress, held in Madrid, Spain, and virtually, ...
They also argued that ADL’s position on the conflict no longer reflected ... Many of these are centered around the platform’s editorial biases and uneven application of its rules. From accusations of ...